Emerging evidence suggests that histone deacetylase inhibitors (e.g., chidamide) could enhance treatment efficacy in patients with MPAL with DNMT3A and NOTCH1 mutations by targeting epigenetic and transcriptional dysregulation (29). The gene discussed is DNMT3A; the disease is mixed phenotype acute leukemia.